Explanipedia

Differentiating Benign and Malignant Solitary Pulmonary Nodules Through Exhaled Breath Analysis Open

Kathleen Zwijsen, Reinier Wener, Ellen Heirwegh, Jan P. van Meerbeeck, Eline Schillebeeckx , et al. · 2025

Lung cancer remains the leading cause of cancer-related deaths worldwide, with early detection significantly improving survival. Lung nodules are a common finding, both as incidental solitary pulmonary nodules (SPNs) and in lung cancer scr…

Co-targeting of VEGFR2 and PD-L1 promotes survival and vasculature normalization in pleural mesothelioma Open

Sophie Rovers, Jonas Van Audenaerde, Ruben Verloy, Jorrit De Waele, Louize Brants , et al. · 2025

Pleural mesothelioma (PM) is an aggressive cancer caused by asbestos exposure, with limited treatment options and poor prognosis, highlighting the need for more effective therapies. Combining immune checkpoint blockade with anti-angiogenic…

A Minimally Invasive Transthoracic Injection Technique for Reproducible Intrapleural Delivery in Mice Open

Sophie Rovers, Pooyeh Farahmand, Dana Liu, Louize Brants, Christophe Hermans , et al. · 2025

The development of standardised, reproducible preclinical models is essential for advancing pleural mesothelioma (PM) research. Here, we present a simple and reliable minimally invasive transthoracic intrapleural injection technique that c…

Prognostic value of baseline EORTC QLQ-C30 scores for overall survival across 46 clinical trials covering 17 cancer types: a validation study Open

Lynn Lim, Abigirl Machingura, Mekdes Taye, Madeline Pe, Corneel Coens , et al. · 2025

Genome-wide DNA methylation analysis reveals a unique methylation pattern for pleural mesothelioma compared to healthy pleura and other lung diseases Open

Janah Vandenhoeck, Joe Ibrahim, Nele De Meulenaere, Dieter Peeters, Jo Raskin , et al. · 2024

A randomised phase II study of extended pleurectomy/decortication preceded or followed by chemotherapy in patients with early-stage pleural mesothelioma: EORTC 1205 Open

Jo Raskin, Veerle Surmont, Alexander P.W.M. Maat, Maha Yahia, Sjaak A. Burgers , et al. · 2024

Background The role of surgery in pleural mesothelioma remains controversial. It may be appropriate in highly selected patients as part of a multimodality treatment including chemotherapy. Recent years have seen a shift from extrapleural p…

Long-Term Outcomes After Concurrent Once- or Twice-Daily Chemoradiation in Limited-Stage Small Cell Lung Cancer: A Brief Report From the CONVERT Trial Open

Gerard Walls, Hitesh Mistry, Fabrice Barlési, Andrea Bezjak, C. Le Péchoux , et al. · 2024

As the CONVERT trial did not demonstrate the superiority of OD RT and this regimen had a slightly worse toxicity profile after 80 months of follow-up, 45 Gy BD should remain the standard of care in limited stage small cell lung cancer.

193O Long-term outcomes after concurrent once- or twice-daily chemoradiation in limited-stage small cell lung cancer: A brief report from the CONVERT trial Open

Gerard Walls, Hitesh Mistry, Fabrice Barlési, Andrea Bezjak, C. Le Péchoux , et al. · 2024

CONVERT was a phase III international randomized clinical trial comparing once-daily (OD) and twice-daily (BD) radiation therapy (RT). This updated analysis describes the 6.5 year outcomes of these regimes delivered with conformal techniqu…

All.Can Belgium’s CB Working Group in the starting-blocks Open

Ingel Demedts, Jan P. van Meerbeeck, Ahmad Awada, Thierry Berghmans · 2024

All.Can Belgium is a multi-stakeholder, not-for-profit organization dedicated to improving the efficiency of cancer care by putting the needs and well-being of patients at the heart of its priorities. In this spirit, All. Can Belgium bring…

Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B Open

Xiuning Le, Luís Paz-Ares, Jan P. van Meerbeeck, Santiago Viteri, Carlos Cabrera Galvez , et al. · 2023

High-level MET amplification (METamp) is a primary driver in ∼1%-2% of non-small cell lung cancers (NSCLCs). Cohort B of the phase 2 VISION trial evaluates tepotinib, an oral MET inhibitor, in patients with advanced NSCLC with high-level M…

P2.21-07 A Novel Proteomic Technique Uncovers New Diagnostic Biomarkers for Malignant Pleural Mesothelioma Open

Kevin Lamote, E. Schillebeeckx, E Fernández, An Staes, Jan P. van Meerbeeck , et al. · 2023

MA17.03 Determining the Clinical Utility of a Breath Test to Screen Asbestos-Exposed Persons for Pleural Mesothelioma Open

Kevin Lamote, K. Zwijsen, Edward Schillebeeckx, Joris Van Cleemput, Caroline Jonckheere , et al. · 2023

ERS/ESTS/ESTRO/ESR/ESTI/EFOMP statement on management of incidental findings from low dose CT screening for lung cancer Open

Emma O’Dowd, Ilona Tietzova, Emily Bartlett, Anand Devaraj, Jürgen Biederer , et al. · 2023

Background Screening for lung cancer with low radiation dose computed tomography has a strong evidence base, is being introduced in several European countries and is recommended as a new targeted cancer screening programme. The imperative …

ERS/ESTS/ESTRO/ESR/ESTI/EFOMP statement on management of incidental findings from low dose CT screening for lung cancer Open

Emma O’Dowd, Ilona Tietzova, Emily Bartlett, Anand Devaraj, Jürgen Biederer , et al. · 2023

Background Screening for lung cancer with low radiation dose computed tomography has a strong evidence base, is being introduced in several European countries and is recommended as a new targeted cancer screening programme. The imperative …

Health Outcomes with Curative and Palliative Therapies in Real World: Role of the Quality of Life Summary Score in Thoracic Oncology Patients Open

Kurt G. Tournoy, Valerie Adam, Inge Muylle, Helene De Rijck, Ellen Everaert , et al. · 2023

Background: For patients receiving therapy with curative or palliative intent for a thoracic malignancy, prediction of quality of life (QOL), once therapy starts, remains challenging. The role of health assessments by the patient instead o…

Developing a pan-European technical standard for a comprehensive high-quality lung cancer computed tomography screening programme: an ERS technical standard Open

David Baldwin, Emma O’Dowd, Ilona Tietzova, Anna Kerpel-Fronius, Marjolein A. Heuvelmans , et al. · 2023

Background Screening for lung cancer with low radiation dose computed tomography (LDCT) has a strong evidence base. The European Council adopted a recommendation in November 2022 that lung cancer screening (LCS) be implemented using a step…

Endosonography With or Without Confirmatory Mediastinoscopy for Resectable Lung Cancer: A Randomized Clinical Trial Open

Jelle E. Bousema, Marcel G. W. Dijkgraaf, Erik H.F.M. van der Heijden, Ad F. T. M. Verhagen, Jouke T. Annema , et al. · 2023

PURPOSE Resectable non–small-cell lung cancer (NSCLC) with a high probability of mediastinal nodal involvement requires mediastinal staging by endosonography and, in the absence of nodal metastases, confirmatory mediastinoscopy according t…

IASLC Lung Cancer Staging Project: The New Database to Inform Revisions in the Ninth Edition of the TNM Classification of Lung Cancer Open

Hisao Asamura, Katherine K. Nishimura, Dorothy J. Giroux, Kari Chansky, Antje Hoering , et al. · 2023

Surgical series in mesothelioma: navigating between biases Open

Jo Raskin, Paul E. Van Schil, Jan P. van Meerbeeck · 2023

Editorial: Imaging assessment of response to immunotherapy Open

Mariaelena Occhipinti, Andrea Riccardo Filippi, Seán Walsh, Jan P. van Meerbeeck · 2023

EDITORIAL article Front. Oncol., 20 January 2023Sec. Cancer Immunity and Immunotherapy Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.1116315

Challenges and knowledge gaps with immune checkpoint inhibitors monotherapy in the management of patients with non-small-cell lung cancer: a survey of oncologist perceptions Open

Luis Castelo‐Branco, Gilberto Morgan, Arsela Prelaj, Matthias Scheffler, Helena Canhão , et al. · 2023

A Cross-Sectional Study on the Acceptability of Implementing a Lung Cancer Screening Program in Belgium Open

Paloma Diab Garcia, Annemiek Snoeckx, Jan P. van Meerbeeck, Guido Van Hal · 2022

Lung cancer is the most common and deadliest cancer in the world, and its incidence is expected to grow. Nonetheless, this growth can be contained through smoking cessation programs and effective lung cancer screening programs. In 2018, Be…

Preclinical evaluation of <span>CDK4</span> phosphorylation predicts high sensitivity of pleural mesotheliomas to <span>CDK4</span> /6 inhibition Open

Sabine Paternot, Eric Raspé, Clément Meiller, Maxime Tarabichi, Jean‐Baptiste Assié , et al. · 2022

Malignant pleural mesothelioma (MPM) is an aggressive cancer with limited therapeutic options. We evaluated the impact of CDK4/6 inhibition by palbociclib in 28 MPM cell lines including 19 patient‐derived ones, using various approaches inc…

The need for a comprehensive and integrated approach to lung cancer policy in Europe Open

Monica Racovita, Eleanor Wheeler, Suzanne Wait, Tit Albreht, Anne‐Marie Baird , et al. · 2022

How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma? Open

Denis Horgan, Anne‐Marie Baird, Mark R. Middleton, Zhasmina Mihaylova, Jan P. van Meerbeeck , et al. · 2022

Cancer is the second leading cause of mortality in EU countries, and the needs to tackle cancer are obvious. New scientific understanding, techniques and methodologies are opening up horizons for significant improvements in diagnosis and c…

New Implications of Patients’ Sex in Today’s Lung Cancer Management Open

Jo Raskin, Annemiek Snoeckx, Annelies Janssens, Charlotte De Bondt, Reinier Wener , et al. · 2022

This paper describes where and how sex matters in today’s management of lung cancer. We consecutively describe the differences between males and females in lung cancer demographics; sex-based differences in the immune system (including the…

External Validation of a Breath-Based Prediction Model for Malignant Pleural Mesothelioma Open

Eline Janssens, Eline Schillebeeckx, Kathleen Zwijsen, Jo Raskin, Joris Van Cleemput , et al. · 2022

During the past decade, volatile organic compounds (VOCs) in exhaled breath have emerged as promising biomarkers for malignant pleural mesothelioma (MPM). However, as these biomarkers lack external validation, no breath test for MPM has be…

Are anaplastic lymphoma kinase (ALK) and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation driver biomarkers of pulmonary neuroendocrine tumors (NETs) and carcinomas (NECs)? Open

Birgitta I. Hiddinga, Karen Zwaenepoel, Annelies Janssens, Jan P. van Meerbeeck, Patrick Pauwels · 2022

Routine testing of NET and NEC samples for an ALK rearrangement is not recommended as ALK-expression is not associated with an ALK-rearrangement. Routine testing of NET and NEC samples for MGMT will detect a promoter hypermethylation in a …

Clustering of EORTC QLQ-C30 health-related quality of life scales across several cancer types: Validation study Open

Abigirl Machingura, Mekdes Taye, Jammbe Musoro, Jolie Ringash, Madeline Pe , et al. · 2022

Lung Cancer Screening: New Perspective and Challenges in Europe Open

Jan P. van Meerbeeck, Emma O’Dowd, Brian Ward, Paul Van Schil, Annemiek Snoeckx · 2022

Randomized-controlled trials have shown clear evidence that lung cancer screening with low-dose CT in a high-risk population of current or former smokers can significantly reduce lung-cancer-specific mortality by an inversion of stage dist…

Jan P. van Meerbeeck YOU? Author Swipe